Supplementary Figure from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
Xiaohua Wu(Fudan University Shanghai Cancer Center), Beihua Kong(Shandong University), Mei Pan(Sir Run Run Shaw Hospital), Xiyan Mu(Shenyang Agricultural University), Qinglei Gao(Tongji Hospital), Songling Zhang(Jilin University), Ying Cheng(Jilin Province Tumor Hospital), Zhongqiu Lin, Yunong Gao, Rutie Yin(Sichuan University), Li Wang, Miao Li, Li Li, Jing Wang(Shanghai Jiao Tong University), Xiuli Wang(Dalian Medical University), Hong Shi(Chinese Academy of Sciences), Xiuping Du, Qi Zhou(Chongqing University), Guiling Li(Qingdao University), Ge Lou(Harbin Medical University), Yi Huang(Shenzhen Institutes of Advanced Technology), Song Mu, Danbo Wang(Qinghai University), Wei Sun(University of Central Florida), Jianqing Zhu
Cited by 0
Related Papers
Correction: Corrigendum: The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes
|Scientific Reports|2016|2.1k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k